Arkolith/Insider Trading/INZY/Form 4

Bolte Axel

DirectorInozyme Pharma, Inc. (INZY) · full profile →Form 4 · filed Jul 3, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 1, 2025Tender(U)424K$4.00$1.7M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 1, 2025Disposed to issuer(D)159K——0
Jul 1, 2025Disposed to issuer(D)234K——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-094096) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML